Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Camrelizumab and GSC-DCV for Recurrent Glioblastoma
NCT04888611Phase 2Unknown
- Sponsor
- Huashan Hospital
- Start
- Oct 2021
- Primary completion
- May 2023
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of GSC-DCV in glioblastoma (GBM), sponsored by Huashan Hospital. Status: unknown.
02
Drugs
GSC-DCV
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04888611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04888611.